Detection of local tumor progression by 18F-FDG PET/Ct following lung radiofrequency ablation: PET versus CT

Clinical Nuclear Medicine

Volumn 38, Issue 4, 2013, Pages

  Suzawa, Naohisa ^a   Yamakado, Koichiro ^a   Takao, Motoshi ^b   Taguchi, Osamu ^c   Yamada, Tomomi ^d   Takeda, Kan ^a  

^a Departments of Radiology   (Japan)

^b Thoracic Surgery   (Japan)

^c Internal Medicine   (Japan)

^d MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

FDG PET CT; local tumor progression; lung; RF ablation

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SIZE; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DRUG UPTAKE; FEMALE; FOLLOW UP; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; RADIOFREQUENCY ABLATION; RADIOLOGICAL PARAMETERS; RECEIVER OPERATING CHARACTERISTIC; STANDARDIZED UPTAKE VALUE;

ADULT; AGED; AGED, 80 AND OVER; CATHETER ABLATION; COLONIC NEOPLASMS; DISEASE PROGRESSION; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; ROC CURVE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84875219906     PISSN: 03639762     EISSN: 15360229     Source Type: Journal    
DOI: 10.1097/RLU.0b013e31828166f6     Document Type: Article

References (29)

1. Sullivan V, Tran T, Holmstrom A, et al. Advanced age does not exclude lobectomy for nonYsmall cell lung carcinoma. Chest. 2005;128:2671-2676.
2. Jensen AD, Munter MW, Bischoff H, et al. Treatment of nonYsmall cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: The NEAR protocol (NCT00115518). BMC Cancer. 2006;6:122.
3. Tan KK, Lopes Gde L Jr, Sim R. How uncommon are isolated lung metastases in colorectal cancer? A review from database of 754 patients over 4 years. J Gastrointest Surg. 2009;13:642-648.
4. Dupuy DE, Zagoria RJ, AkerleyW, et al. Percutaneous radiofrequency ablation of malignancies in the lung. AJR Am J Roentgenol. 2000;174:57-59.
5. Steinke K, King J, Glenn D, et al. Radiologic appearance and complications of percutaneous computed tomographyYguided radiofrequency-ablated pulmonary metastases from colorectal carcinoma. J Comput Assist Tomogr. 2003;27: 750-757.
6. Yasui K, Kanazawa S, Sano Y, et al. Thoracic tumors treated with CT-guided radiofrequency ablation: Initial experience. Radiology. 2004;231:850-857.
7. Bojarski JD, Dupuy DE, Mayo-SmithWW. CT imaging findings of pulmonary neoplasms after treatment with radiofrequency ablation: Results in 32 tumors. AJR Am J Roentgenol. 2005;185:466-471.
8. Yamakado K, Hase S, Matsuoka T, et al. Radiofrequency ablation for the treatment of unresectable lung metastases in patients with colorectal cancer: A multicenter study in Japan. J Vasc Interv Radiol. 2007;18:393-398.
9. Hiraki T, Mimura H, Gobara H, et al. Repeat radiofrequency ablation for local progression of lung tumors: Does it have a role in local tumor control? J Vasc Interv Radiol. 2008;19:706-711.
10. Yamamoto A, Nakamura K, Matsuoka T, et al. Radiofrequency ablation in a porcine lung model: Correlation between CTand histopathologic findings. AJR Am J Roentgenol. 2005;185:1299-1306.
11. Lardinois D, Weder W, Hany TF, et al. Staging of nonYsmall-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
12. Antoch G, Stattaus J, Nemat AT, et al. NonYsmall cell lung cancer: Dualmodality PET/CT in preoperative staging. Radiology. 2003;229:526-533.
13. Herrera LJ, Fernando HC, Perry Y, et al. Radiofrequency ablation of pulmonary malignant tumors in nonsurgical candidates. J Thorac Cardiovasc Surg. 2003;125:929-937.
14. Akeboshi M, Yamakado K, Nakatsuka A, et al. Percutaneous radiofrequency ablation of lung neoplasms: Initial therapeutic response. J Vasc Interv Radiol. 2004;15:463-470.
15. Okuma T, Okamura T, Matsuoka T, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for assessment of patients with unresectable recurrent or metastatic lung cancers after CT-guided radiofrequency ablation: Preliminary results. Ann Nucl Med. 2006;20:115-121.
16. Yamagami T, Kato T, Hirota T, et al. Risk factors for occurrence of local tumor progression after percutaneous radiofrequency ablation for lung neoplasms. Diagn Interv Radiol. 2007;13:199-203.
17. Higaki F, Okumura Y, Sato S, et al. Preliminary retrospective investigation of FDG-PET/CT timing in follow-up of ablated lung tumor. Ann Nucl Med. 2008;22:157-163.
18. Beland MD, Wasser EJ, Mayo-Smith WW, et al. Primary nonYsmall cell lung cancer: Reviewof frequency, location, and time of recurrence after radiofrequency ablation. Radiology. 2010;254:301-307.
19. Singnurkar A, Solomon SB, Gonen M, et al. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions. J Nucl Med. 2010;51:1833-1840.
20. Deandreis D, Leboulleux S, Dromain C, et al. Role of FDG PET/CT and chest CT in the follow-up of lung lesions treated with radiofrequency ablation. Radiology. 2011;258:270-276.
21. Purandare NC, Rangarajan V, Shah SA, et al. Therapeutic response to radiofrequency ablation of neoplastic lesions: FDG PET/CT findings. Radiographics. 2011;31:201-213.
22. Katada K, Kato R, Anno H, et al. Guidance with real-time CT fluoroscopy: Early clinical experience. Radiology. 1996;200:851-856.
23. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: Review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 1999;35:1773-1782.
24. Wahl RL, Jacene H, Kasamon Y, et al. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009; 50(suppl 1):122SY150S.
25. Miller AB, Hoogstraten B, Staquet M, et al. Reporting results of cancer treatment. Cancer. 1981;47:207-214.
26. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
27. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-247.
28. de Baere T, Palussiere J, Auperin A, et al. Midterm local efficacy and survival after radiofrequency ablation of lung tumors with minimum follow-up of 1 year: Prospective evaluation. Radiology. 2006;240:587-596.
29. Lencioni R, Crocetti L, Cioni R, et al. Response to radiofrequency ablation of pulmonary tumours: A prospective, intention-to-treat, multicentre clinical trial (the RAPTURE study). Lancet Oncol. 2008;9:621-628.